Indian pharmaceutical giant Cipla is exploring at least two new overseas markets for products made at its Chinese manufacturing plant, as it grapples with limited production capacity in India. The company began producing inhalation respule products at its Jiangsu facility in 2024 to supply the U.S., and is now in talks with other countries to expand exports.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eEWsRNJ
via IFTTT
-
Acquista ********, Ossicodone, Ketamina, Ozempic (WhatsApp: +31616337954) I nostri prodotti hanno una purezza del 98-99%. E-mail di cont...
-
So I’m currently on a lean bulk on 2900 a day. And I wake up 6 am I have oats and protein powder or fruit then go gym around 9 am Then at ...
-
Kotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient...
Search This Blog
Powered by Blogger.
Recent Posts
Unordered List
Theme Support
-
Text Widget
Design by FlexiThemes | Blogger Theme by Lasantha - PremiumBloggerTemplates.com | Best Gadgets | Distributed By Gooyaabi Templates
0 comments:
Post a Comment